The authors designed BR.26 to assess whether dacomitinib improved overall survival in heavily pretreated patients with this disease. Dacomitinib did not increase overall survival and cannot be recommended for treatment of patients with advanced non-small-cell lung cancer previously treated with chemotherapy and an EGFR tyrosine-kinase inhibitor.

READ FULL ARTICLE Curated publisher From Mdlinx